CRISPR

CRISPR
Name	CRISPR
Invented	1987
Inventor	Francisco Mojica; Yoshizumi Ishino
Field	Molecular biology; Genetics; Biotechnology

Contents

CRISPR CRISPR is a family of DNA sequences in prokaryotic genomes used in adaptive immunity and repurposed as a programmable gene-editing system. It transformed biological research and biotechnology, enabling targeted modification of genomes across taxa, and catalyzed intersections among institutions such as the Broad Institute, Max Planck Society, Howard Hughes Medical Institute, Wellcome Trust, and companies including Editas Medicine, Intellia Therapeutics, CRISPR Therapeutics, Bayer.

History

The system functions via programmable nucleic-acid guidance first characterized in Streptococcus thermophilus, Escherichia coli, Sulfolobus solfataricus, and other microbes studied by researchers in labs at Institut Pasteur and Institut Pasteur de Montevideo. Components include CRISPR arrays discovered in datasets from European Molecular Biology Laboratory, processed into CRISPR RNAs by factors shared with systems characterized at Cold Spring Harbor Laboratory and Max Planck Institute for Infection Biology. Target recognition couples base-pairing rules elucidated in structural studies from EMBL-EBI, cryo-EM work associated with Harvard Medical School and University of Cambridge, and biochemical assays performed at National Institutes of Health. Cleavage arises from nuclease activity modeled on enzymes described in work from Scripps Research, California Institute of Technology, and Rockefeller University.

Multiple classes and types were classified in taxonomic schemes developed by Eugene Koonin and collaborators at National Center for Biotechnology Information. Class 1 systems with multi-protein effector complexes were characterized in taxa studied at Wageningen University, Chinese Academy of Sciences, and Tokyo Institute of Technology. Class 2 single-effector systems such as Cas9, Cas12, and Cas13 were described in studies from Stanford University, University of Copenhagen, Max Planck Institute for Evolutionary Anthropology, and Peking University. Accessory proteins like tracrRNA, trans-activating RNAs, and PAM-interacting domains were mapped using techniques from Broad Institute, European Bioinformatics Institute, Friedrich Miescher Institute, and ETH Zurich. Engineered variants including base editors and prime editors were developed in labs associated with Harvard University, Broad Institute, University of Tokyo, and Riken.

Genome editing applications span agriculture at corporations like Monsanto and research from International Rice Research Institute, clinical programs at hospitals such as Mayo Clinic and Johns Hopkins Hospital, and industrial biotechnology in firms like DuPont and Novartis. Therapeutic trials have been initiated by Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Sangamo Therapeutics, and academic centers including Massachusetts General Hospital and Stanford Health Care. Model-organism work employs facilities such as Jackson Laboratory, Salk Institute, and Cold Spring Harbor Laboratory. Diagnostics using nucleic acid detection leverage platforms developed at Zymo Research, Sherlock Biosciences, and collaborations with Bill & Melinda Gates Foundation for global health. Conservation projects and synthetic biology initiatives involve NGOs like The Nature Conservancy and research hubs including EMBL and J. Craig Venter Institute.

Debates about germline modification and human enhancement were prominent at gatherings like the International Summit on Human Genome Editing and forums convened by National Academies of Sciences, Engineering, and Medicine, World Health Organization, European Group on Ethics, and advisory bodies in China and United Kingdom. Patent disputes implicated University of California and Broad Institute in litigation before courts such as the United States Court of Appeals for the Federal Circuit and agencies including the European Patent Office. Biosecurity and dual-use concerns were raised by think tanks including Carnegie Endowment for International Peace, RAND Corporation, and policy units at Council on Foreign Relations. Ethical scholarship from scholars affiliated with Harvard Kennedy School, Oxford University, Yale Law School, and Princeton University shaped governance proposals and public consultations supported by funders like Wellcome Trust and Gates Foundation.

Limitations include off-target effects characterized in studies at Broad Institute and MIT, delivery challenges addressed by teams at Genentech, Moderna, Alnylam Pharmaceuticals, and Bluebird Bio, and immunogenicity concerns investigated at National Institutes of Health and Fred Hutchinson Cancer Research Center. Scale-up and manufacturing constraints involve standards set by International Organization for Standardization and regulatory pathways through European Medicines Agency and U.S. Food and Drug Administration. Resistance and escape in microbial populations were documented in research from University of Edinburgh, Wageningen University, and Max Planck Institute for Evolutionary Biology, prompting continued innovation in high-fidelity variants and delivery vehicles from entities such as Zymergen and academic consortia at Wellcome Sanger Institute.